BDTX Black Diamond Therapeutics Inc

Price (delayed)

$24.58

Market cap

$888.26M

P/E Ratio

N/A

Dividend/share

N/A

EPS

-$2.05

Enterprise value

$860.13M

Sector: Healthcare
Industry: Biotechnology

Highlights

Black Diamond Therapeutics's EPS has surged by 88% YoY and by 66% QoQ
The net income has plunged by 91% YoY and by 23% from the previous quarter
The quick ratio has contracted by 30% YoY and by 25% from the previous quarter

Key stats

What are the main financial stats of BDTX
Market
Shares outstanding
36.14M
Market cap
$888.26M
Enterprise value
$860.13M
Valuations
Price to earnings (P/E)
N/A
Price to book (P/B)
2.87
Price to sales (P/S)
N/A
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
N/A
Earnings
Revenue
$0
EBIT
-$67.25M
EBITDA
-$67.2M
Free cash flow
-$52.29M
Per share
EPS
-$2.05
Free cash flow per share
-$1.59
Book value per share
$8.55
Revenue per share
$0
TBVPS
$10.02
Balance sheet
Total assets
$329.67M
Total liabilities
$21.91M
Debt
$7.69M
Equity
$307.76M
Working capital
$305.34M
Liquidity
Debt to equity
0.03
Current ratio
22.48
Quick ratio
22.25
Net debt/EBITDA
0.42
Margins
EBITDA margin
N/A
Gross margin
N/A
Net margin
N/A
Operating margin
N/A
Efficiency
Return on assets
-19.4%
Return on equity
-20.2%
Return on invested capital
-31.6%
Return on capital employed
-21.3%
Return on sales
N/A
Dividend
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A

BDTX stock price

How has the Black Diamond Therapeutics stock price performed over time
Intraday
-4.95%
1 week
-0.69%
1 month
-2.11%
1 year
-17.65%
YTD
-23.31%
QTD
1.32%

Financial performance

How have Black Diamond Therapeutics's revenue and profit performed over time
Revenue
$0
Gross profit
$0
Operating income
-$69.57M
Net income
-$67.25M
Gross margin
N/A
Net margin
N/A
BDTX's operating income has shrunk by 137% YoY and by 23% QoQ
The net income has plunged by 91% YoY and by 23% from the previous quarter

Growth

What is Black Diamond Therapeutics's growth rate over time

Valuation

What is Black Diamond Therapeutics stock price valuation
P/E
N/A
P/B
2.87
P/S
N/A
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
N/A
Black Diamond Therapeutics's EPS has surged by 88% YoY and by 66% QoQ
The P/B is 14% lower than the last 4 quarters average of 3.5
The company's equity fell by 6% QoQ

Efficiency

How efficient is Black Diamond Therapeutics business performance
The ROA rose by 42% YoY but it fell by 8% QoQ
BDTX's return on invested capital is up by 19% since the previous quarter
Black Diamond Therapeutics's ROE has increased by 9% from the previous quarter

Dividends

What is BDTX's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A

There are no recent dividends present for BDTX.

Financial health

How did Black Diamond Therapeutics financials performed over time
Black Diamond Therapeutics's total assets has soared by 108% YoY but it has decreased by 4.8% from the previous quarter
BDTX's current ratio is down by 30% year-on-year and by 24% since the previous quarter
The debt is 97% smaller than the equity
Black Diamond Therapeutics's debt to equity has surged by 50% QoQ
The company's equity fell by 6% QoQ

All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.